BackSkye Bioscience Overview

Skye Bioscience Current Cash

Track Skye Bioscience's current cash ($8.1M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$8.07M
↓ 66.15% YoYΔ $-15.77M vs prior year quarter

Peer trimmed avg / median

Loading

Skye Bioscience Current Cash History

Loading

Skye Bioscience vs. peers: Current Cash Comparison

Loading

Skye Bioscience Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Skye Bioscience (SKYE) FAQ

The latest current cash for SKYE is $8.1M as of June 2026. That compares with $24M in the prior-year period — down 66.2% year over year. Investors often review this figure alongside Skye Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, SKYE's current cash moved from $24M to $8.1M — a 66.2% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Skye Bioscience's operating scale or balance-sheet position.

A current cash figure of $8.1M for SKYE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting SKYE's current cash ($8.1M), review year-over-year change from $24M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.